Ombrabulin
CAS: 181816-48-8
Ref. 3D-GHA81648
1mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen |
Produktinformation
- (2S)-2-Amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide
- Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-, (2S)-
- Propanamide, 2-amino-3-hydroxy-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-, [S-(Z)]-
Ombrabulin is a potential anticancer agent that inhibits the formation of new blood vessels in solid tumours. It blocks angiogenesis, the process by which new blood vessels are formed from existing ones. Ombrabulin does not affect normal cells and is rapidly cleared from the body with no apparent side effects. Ombrabulin has been shown to be effective against docetaxel-resistant breast cancer in animal models, and it may also be active against other solid tumours such as prostate cancer. Ombrabulin binds to the AT1 receptor and activates a G-protein coupled receptor signaling pathway, resulting in inhibition of angiogenesis.